Cadrenal Therapeutics, Inc.
CVKD
$1.19
-$0.01-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 18.17% | 7.36% | -24.28% | -89.08% | -126.20% |
| Total Depreciation and Amortization | -68.66% | -70.59% | 263.16% | 219.05% | 191.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.84% | -8.94% | 36.74% | 213.47% | 260.27% |
| Change in Net Operating Assets | -249.39% | -183.58% | -169.99% | -69.55% | -75.40% |
| Cash from Operations | 12.89% | -7.72% | -71.28% | -88.82% | -148.87% |
| Capital Expenditure | 80.61% | 80.61% | 20.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.90% | 80.61% | 20.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -38.54% | -10.12% | 39.19% | 362.77% | 30.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -52.75% | -114.45% | -114.68% | 3,586.92% | -- |
| Cash from Financing | -42.83% | -45.85% | -26.54% | 647.53% | 87.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -696.55% | -753.31% | -472.05% | 89.38% | -70.48% |